Shionogi Europe

Shionogi Europe company information, Employees & Contact Information

Explore related pages

Related company profiles:

Shionogi B.V. (known as “Shionogi Europe”) is the European headquarters of Shionogi & Co., Ltd, a leading global research-driven pharmaceutical company based in Osaka, Japan. Since 1878, Shionogi has been striving to supply the best possible medicines to protect the health and wellbeing of the patients we serve. We are dedicated to finding innovative solutions for pressing unmet clinical needs, and have a strong track record in discovering and developing novel medicines for antimicrobial resistance (AMR), HIV and influenza. Alongside our work in infectious diseases, we also have extensive expertise in other areas of unmet clinical needs within our Hospital Specialty Business, and a strong track record in other therapy areas affecting quality of life, particularly Women’s Health. Since launching in Europe in 2012, we have significantly expanded our presence and now have coverage of the biggest markets in the continent. Our offices in Amsterdam, Berlin, London, Madrid, Paris and Rome provide the bases for over 300 passionate staff from across the spectrum of big pharma and biotech, as well as experts in technology, creatives, entrepreneurs and others - who come together to do things differently and better. Our culture is unique, blending our Japanese roots with our strong and rapidly growing European operation. We have a friendly, inclusive work environment and aim to foster a culture that encourages our people to break out of the boundaries of the traditional pharmaceutical company. Through successful strategic partnerships and open collaboration, we are determined to shape the future of healthcare. Our ambitious growth plans include extending the reach of our marketed products, developing our innovative pipeline of medicines and securing the right partnerships and acquisitions to accelerate our development. To find out about partnering with us, visit: https://t.ly/YzlSu For career opportunities, visit: https://t.ly/mERcQ NP-EU-NP-0303 DOP July 2024

Company Details

Employees
288
Founded
-
Address
Herengracht 464, Amsterdam,north Holland 1017 Bz,netherlands
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Engineer jobs.
HQ
Amsterdam, North Holland
Looking for a particular Shionogi Europe employee's phone or email?

Shionogi Europe Questions

News

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek - Business Wire

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek Business Wire

Preparing Europe for the next cross-border health threats, COVID lessons unpacked - Euractiv

Preparing Europe for the next cross-border health threats, COVID lessons unpacked Euractiv

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure - Business Wire

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Business Wire

Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries - Clinton Health Access Initiative

Shionogi, GARDP, and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries Clinton Health Access Initiative

History - Shionogi Inc.

History Shionogi Inc.

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - Contagion Live

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention Contagion Live

After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug - statnews.com

After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug statnews.com

F2G enlists Shionogi to bring antifungal treatment to Europe and Asia - Labiotech.eu

F2G enlists Shionogi to bring antifungal treatment to Europe and Asia Labiotech.eu

Shionogi Europe and NHS England agree on antibiotic subscription model - PMLiVE

Shionogi Europe and NHS England agree on antibiotic subscription model PMLiVE

IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections - BioSpace

IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections BioSpace

Shionogi's antiviral comes up short in global COVID-19 trial - Fierce Pharma

Shionogi's antiviral comes up short in global COVID-19 trial Fierce Pharma

Safeguarding the future: protecting the pipeline of antimicrobial medicines - Raconteur

Safeguarding the future: protecting the pipeline of antimicrobial medicines Raconteur

Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld MedTech

Shionogi to acquire Japan Tobacco pharma companies for $1.1B BioWorld MedTech

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations - Business Wire

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations Business Wire

Shionogi lifts profit outlook on HIV royalties and overseas growth - The Japan Times

Shionogi lifts profit outlook on HIV royalties and overseas growth The Japan Times

Antibiotics, an important but tricky business, says Shionogi CEO - Euractiv

Antibiotics, an important but tricky business, says Shionogi CEO Euractiv

Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Headquarters in Amsterdam - Business Wire

Leading Japanese Pharmaceutical Company, Shionogi, Officially Opens Doors of Its New European Headquarters in Amsterdam Business Wire

Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats - Business Wire

Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats Business Wire

Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections - Business Wire

Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections Business Wire

Shionogi’s Antibiotic, FETCROJA® (cefiderocol), Is Now Available in the Netherlands - Business Wire

Shionogi’s Antibiotic, FETCROJA® (cefiderocol), Is Now Available in the Netherlands Business Wire

ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S‑217622 - Business Wire

ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S‑217622 Business Wire

Shionogi Launches Fetcroja in Denmark to Treat Aerobic Gram-negative Bacterial Infections - NAVLIN DAILY

Shionogi Launches Fetcroja in Denmark to Treat Aerobic Gram-negative Bacterial Infections NAVLIN DAILY

EC approves Shionogi’s new antibiotic Fetcroja - PharmaTimes

EC approves Shionogi’s new antibiotic Fetcroja PharmaTimes

Combatting antimicrobial resistance: a doctor’s perspective - Raconteur

Combatting antimicrobial resistance: a doctor’s perspective Raconteur

F2G Announces Publication in The Lancet Infectious Diseases - GlobeNewswire

F2G Announces Publication in The Lancet Infectious Diseases GlobeNewswire

Shionogi launches novel antibiotic Fetcroja in the UK - PharmaTimes

Shionogi launches novel antibiotic Fetcroja in the UK PharmaTimes

Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 - PR Newswire

Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 PR Newswire

Last-resort antibiotic excluded from Belgian system, testing EU pharma reforms - Euractiv

Last-resort antibiotic excluded from Belgian system, testing EU pharma reforms Euractiv

NHS launches ‘subscription’ scheme for antibiotics with pharma sector - Financial Times

NHS launches ‘subscription’ scheme for antibiotics with pharma sector Financial Times

Duchesnay Expands Its Women's Health Product Portfolio With Acquisition Of Osphena® From Shionogi Inc. - PR Newswire

Duchesnay Expands Its Women's Health Product Portfolio With Acquisition Of Osphena® From Shionogi Inc. PR Newswire

SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC® (NALDEMEDINE), AN OPIOID-INDUCED CONSTIPATION THERAPEUTIC AGENT IN ITALY AND POLAND - DutchNews.nl

SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC® (NALDEMEDINE), AN OPIOID-INDUCED CONSTIPATION THERAPEUTIC AGENT IN ITALY AND POLAND DutchNews.nl

Duchesnay Expands its Women's Health Product Portfolio with Acquisition of Osphena® from Shionogi Inc. - PR Newswire Canada

Duchesnay Expands its Women's Health Product Portfolio with Acquisition of Osphena® from Shionogi Inc. PR Newswire Canada

Top Shionogi Europe Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant